SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Xu Chun Jie) "

Sökning: WFRF:(Xu Chun Jie)

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
3.
  • Zhang, Huai, et al. (författare)
  • A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.
  • 2024
  • Ingår i: Hepatology international. - 1936-0541.
  • Tidskriftsartikel (refereegranskat)abstract
    • With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p=0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%).This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.
  •  
4.
  •  
5.
  • Wang, Anqi, et al. (författare)
  • Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
  • 2023
  • Ingår i: Nature Genetics. - : Springer Nature. - 1061-4036 .- 1546-1718. ; 55:12, s. 2065-2074
  • Tidskriftsartikel (refereegranskat)abstract
    • The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry genome-wide association study of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer genome-wide association studies. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a greater risk of aggressive versus non-aggressive disease in men of African ancestry (P = 0.03). Our study presents novel prostate cancer susceptibility loci and a GRS with effective risk stratification across ancestry groups.
  •  
6.
  • Xu, Chun Kai, et al. (författare)
  • Nonlinear inelastic electron scattering revealed by plasmon-enhanced electron energy-loss spectroscopy
  • 2014
  • Ingår i: Nature Physics. - 1745-2473 .- 1745-2481. ; 10:10, s. 753-757
  • Tidskriftsartikel (refereegranskat)abstract
    • Electron energy-loss spectroscopy is a powerful tool for identifying the chemical composition of materials(1-5). It relies mostly on the measurement of inelastic electrons, which carry specific atomic or molecular information. Inelastic electron scattering, however, has a very low intensity, often orders of magnitude weaker than that of elastically scattered electrons. Here, we report the observation of enhanced inelastic electron scattering from silver nanostructures, the intensity of which can reach up to 60% of its elastic counterpart. A home-made scanning probe electron energy-loss spectrometer(6) was used to produce highly localized plasmonic excitations, significantly enhancing the strength of the local electric field of silver nanostructures. The intensity of inelastic electron scattering was found to increase nonlinearly with respect to the electric field generated by the tip-sample bias, providing direct evidence of nonlinear electron scattering processes.
  •  
7.
  • Conti, David, V, et al. (författare)
  • Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
  • 2021
  • Ingår i: Nature Genetics. - : Springer Nature. - 1061-4036 .- 1546-1718. ; 53:1, s. 65-75
  • Tidskriftsartikel (refereegranskat)abstract
    • Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top genetic risk score (GRS) decile was associated with odds ratios that ranged from 5.06 (95% confidence interval (CI), 4.84-5.29) for men of European ancestry to 3.74 (95% CI, 3.36-4.17) for men of African ancestry. Men of African ancestry were estimated to have a mean GRS that was 2.18-times higher (95% CI, 2.14-2.22), and men of East Asian ancestry 0.73-times lower (95% CI, 0.71-0.76), than men of European ancestry. These findings support the role of germline variation contributing to population differences in prostate cancer risk, with the GRS offering an approach for personalized risk prediction. A meta-analysis of genome-wide association studies across different populations highlights new risk loci and provides a genetic risk score that can stratify prostate cancer risk across ancestries.
  •  
8.
  • Huang, Shan, et al. (författare)
  • Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner
  • 2023
  • Ingår i: Cellular Oncology. - : Springer Science and Business Media LLC. - 2211-3428 .- 2211-3436. ; 46:4, s. 953-967
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: Available evidence indicates that dipyridamole enhances the anti-thrombotic effects of aspirin for the prevention of secondary strokes. Aspirin is a well-known non-steroid anti-inflammatory drug. This anti-inflammatory property has turned aspirin into a potential drug for inflammation-related cancers such as colorectal cancer (CRC). Here, we aimed to explore whether the anti-cancer effect of aspirin against CRC could be improved by combined administration with dipyridamole.METHODS: Population-based clinical data analysis was conducted to assess a possible therapeutic effect of combined dipyridamole and aspirin treatment in inhibiting CRC compared with either monotherapy. This therapeutic effect was further verified in different CRC mouse models, i.e. an orthotopic xenograft mouse model, an AOM/DSS mouse model, an Apc min/+ mouse model and a patient derived xenograft (PDX) mouse model. The in vitro effects of the drugs on CRC cells were tested using CCK8 and flow cytometry assays. RNA-Seq, Western blotting, qRT-PCR and flow cytometry were used to identify the underlying molecular mechanisms. RESULTS: We found that dipyridamole combined with aspirin had a better inhibitory effect on CRC than either monotherapy alone. The enhanced anti-cancer effect of the combined use of dipyridamole with aspirin was found to rely on the induction of an overwhelmed endoplasmic reticulum (ER) stress and subsequent pro-apoptotic unfolded protein response (UPR), which was different from the anti-platelet effect.CONCLUSIONS: Our data indicate that the anti-cancer effect of aspirin against CRC may be enhanced by combined administration with dipyridamole. In case further clinical studies confirm our findings, these may be repurposed as adjuvant agents.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8
Typ av publikation
tidskriftsartikel (8)
Typ av innehåll
refereegranskat (7)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Batra, Jyotsna (3)
Khaw, Kay-Tee (2)
Riboli, Elio (2)
Zhang, Kai (2)
Wolk, Alicja (2)
Donovan, Jenny L (2)
visa fler...
Hamdy, Freddie C (2)
Neal, David E (2)
Eeles, Rosalind A (2)
Haiman, Christopher ... (2)
Kote-Jarai, Zsofia (2)
Benlloch, Sara (2)
Muir, Kenneth (2)
Berndt, Sonja I (2)
Conti, David V (2)
Wiklund, Fredrik (2)
Chanock, Stephen J (2)
Tangen, Catherine M (2)
Clements, Judith A (2)
Pashayan, Nora (2)
Schleutker, Johanna (2)
Albanes, Demetrius (2)
West, Catharine M L (2)
Mucci, Lorelei A (2)
Cancel-Tassin, Geral ... (2)
Koutros, Stella (2)
Maehle, Lovise (2)
Travis, Ruth C (2)
Rosenstein, Barry S (2)
Lu, Yong-Jie (2)
Giles, Graham G (2)
Kibel, Adam S (2)
Vega, Ana (2)
Kogevinas, Manolis (2)
Penney, Kathryn L (2)
Park, Jong Y (2)
Stanford, Janet L (2)
Cybulski, Cezary (2)
Nordestgaard, Borge ... (2)
Brenner, Hermann (2)
Maier, Christiane (2)
Kim, Jeri (2)
John, Esther M (2)
Teixeira, Manuel R (2)
Neuhausen, Susan L (2)
Razack, Azad (2)
Newcomb, Lisa F (2)
Lessel, Davor (2)
Usmani, Nawaid (2)
Claessens, Frank (2)
visa färre...
Lärosäte
Karolinska Institutet (4)
Uppsala universitet (3)
Lunds universitet (3)
Göteborgs universitet (2)
Kungliga Tekniska Högskolan (2)
Stockholms universitet (2)
visa fler...
Umeå universitet (1)
Högskolan i Halmstad (1)
Linköpings universitet (1)
Chalmers tekniska högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (6)
Naturvetenskap (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy